Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)‘s stock had its “overweight” rating restated by stock analysts at Morgan Stanley in a research note issued on Tuesday, MarketBeat reports. They currently have a $38.00 target price on the stock, down from their prior target price of $47.00. Morgan Stanley’s price target points to a potential upside of 14.87% from the stock’s previous close.

A number of other equities research analysts also recently commented on BHVN. Needham & Company LLC dropped their price objective on shares of Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday. BidaskClub raised shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, September 12th. Finally, Zacks Investment Research raised shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $40.80.

Biohaven Pharmaceutical Holding Co (BHVN) traded down 6.97% during mid-day trading on Tuesday, hitting $33.08. The stock had a trading volume of 642,391 shares. Biohaven Pharmaceutical Holding Co has a 52-week low of $17.00 and a 52-week high of $39.51. The firm has a 50-day moving average of $35.38 and a 200-day moving average of $27.66. The stock’s market cap is $1.19 billion.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/03/morgan-stanley-cuts-biohaven-pharmaceutical-holding-co-ltd-bhvn-price-target-to-38-00.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.